Mapping the microcarrier design pathway to modernise clinical mesenchymal stromal cell expansion.

Trends Biotechnol

School of Medical Sciences, University of Sydney, Sydney, Australia; Charles Perkins Centre, University of Sydney, Sydney, Australia; Sydney Nano Institute, University of Sydney, Sydney, Australia. Electronic address:

Published: July 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Microcarrier expansion systems show exciting potential to revolutionise mesenchymal stromal cell (MSC)-based clinical therapies by providing an opportunity for economical large-scale expansion of donor- and patient-derived cells. The poor reproducibility and efficiency of cell expansion on commercial polystyrene microcarriers have driven the development of novel microcarriers with tuneable physical, mechanical, and cell-instructive properties. These new microcarriers show innovation toward improving cell expansion outcomes, although their limited biological characterisation and compatibility with dynamic culture systems suggest the need to realign the microcarrier design pathway. Clear headway has been made toward developing infrastructure necessary for scaling up these technologies; however, key challenges remain in characterising the wholistic effects of microcarrier properties on the biological fate and function of expanded MSCs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tibtech.2024.01.001DOI Listing

Publication Analysis

Top Keywords

cell expansion
12
microcarrier design
8
design pathway
8
mesenchymal stromal
8
stromal cell
8
expansion
5
mapping microcarrier
4
pathway modernise
4
modernise clinical
4
clinical mesenchymal
4

Similar Publications

Antigen-binding proteins, such as nanobodies, modified with functional small molecules hold great potential for applications including imaging probes, drug conjugates, and localized catalysts. However, traditional chemical labeling methods that randomly target lysine or cysteine residues often produce heterogeneous conjugates with limited reproducibility. Conventional site-specific conjugation approaches, which typically modify only the N- or C-terminus, may also be insufficient to achieve the desired functionalities.

View Article and Find Full Text PDF

An integrated framework for evolution of ciliated protists (Protista, Ciliophora) from the perspective of comparative genomics.

Mol Phylogenet Evol

September 2025

Laboratory of Biodiversity and Evolution of Protozoa, College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China. Electronic address:

Early-branching eukaryotes are associated with the early branching events during eukaryogenesis. Understanding their genomic diversity and evolution can provide insights into the origin and speciation of eukaryotes. Ciliated protists (ciliates) are a group of early-branching unicellular eukaryotes with a high biodiversity, making them excellent models for evolutionary studies.

View Article and Find Full Text PDF

Background: In autoimmune disease it is not understood how self-reactive B cells escape immune tolerance checkpoints to produce pathogenic autoantibodies.

Objective: In patients with demyelinating polyneuropathy caused by IgM autoantibodies against myelin associated glycoprotein (MAG) and the sulphated trisaccharide CD57, we aimed to test the hypothesis that B cells making the autoantibody escaped tolerance by acquiring lymphoma driver somatic mutations.

Methods: Deep single-cell RNA, DNA, flow cytometric and antibody specificity analysis of blood from three patients with MAG neuropathy.

View Article and Find Full Text PDF

Human T-cell leukemia virus type I: modulation of viral gene expression and perturbation of host signaling pathways lead to persistent infection.

Curr Opin Virol

September 2025

Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. Electronic address:

Human T-cell leukemia virus type I (HTLV-1) was the first human pathogenic retrovirus to be discovered. HTLV-1 induces a T-cell malignancy, adult T-cell leukemia-lymphoma (ATL), and inflammatory diseases, such as HTLV-1-associated myelopathy (HAM), HTLV-1 uveitis (HU), and HTLV-1-associated pulmonary disease (HAPD). Importantly, HTLV-1 maintains persistent infection by regulating viral gene expression and disrupting host signaling pathways - activities that are closely linked to its pathogenicity.

View Article and Find Full Text PDF

Injections have been linked to feline sarcomas (feline injection-site sarcoma; FISS) and cutaneous lymphomas (cutaneous lymphoma at injection site; CLIS). Both tumors often exhibit lymphoplasmacytic inflammation ascribed to injected immunogenic material. CLIS is hypothesized to emerge from transformation and clonal expansion of lymphoid cells following persistent immune stimulation with feline leukemia virus (FeLV) reactivation and transformation.

View Article and Find Full Text PDF